SRRK is a 5/18 IPO focusing on localized protein growth factors. Other biotech firms focusing on protein growth factors do so in a systemic way that does not control side effects well. The lead program is a selective inhibitor of Myostatin activation aimed at reversing/preventing spinal muscle atrophy. Cash runway extends into 2020 but dilution is likely in 2019.